The short version of PT-141 code fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2026-08-01. Anything still debated is marked as such rather than presented as settled.
Bremelanotide acts as an agonist at melanocortin receptors, a family of five G-protein-coupled receptors labeled MC1 through MC5. Binding studies indicate activity at several of these subtypes rather than strict selectivity for one. Signalling proceeds mainly through Gs-mediated activation of adenylyl cyclase, raising intracellular cyclic AMP. The MC4 receptor, expressed in hypothalamic and limbic circuits, is widely regarded as the subtype most relevant to sexual response. Because the molecule is not subtype-selective, effects at other melanocortin receptors are expected and are used to explain some observed side effects.
The peptide contains seven amino acids arranged in a ring, closed by a lactam bridge between a side-chain acid and an amine. This cyclic constraint holds the backbone in a defined conformation and increases resistance to enzymatic breakdown relative to linear analogs. N-terminal acetylation and a C-terminal amide further protect the molecule from exopeptidases. The result is a compound with a comparatively long circulation time for a small peptide. Structural modification of the bridge alters receptor affinity, which is one reason analogs in this family differ in their subtype preferences.
Whether the behavioral effect originates centrally, peripherally, or through both remains an active question. Animal experiments using receptor antagonists and site-specific injections point toward hypothalamic melanocortin circuits as a key locus, but translating those findings to humans is not straightforward. Blood pressure changes observed in trials suggest a vascular component that may be peripherally mediated. The relationship between receptor occupancy and reported effect has not been mapped in humans, and no validated biomarker predicts response. This gap makes it difficult to explain individual variability on pharmacological grounds alone.
The compound emerged from a research programme examining melanocortin analogues for effects on skin pigmentation. During early human studies, participants reported spontaneous erections as an unexpected side effect, which redirected development toward sexual function rather than tanning. An intranasal formulation was investigated in clinical trials but did not reach market approval. A subcutaneous injectable version later completed the regulatory process, and the nasal route does not appear in approved labelling.
Approved use is narrow and jurisdiction-specific. In the United States, the injectable product is authorised for premenopausal women with acquired, generalised hypoactive sexual desire disorder, a diagnosis that requires documented distress. It is not approved for men, for postmenopausal women, or for use alongside hormonal contraceptives under the approved labelling. Outside regulated markets, the same peptide is frequently sold as a research chemical, where identity, purity, and sterility are not independently verified.
Bremelanotide is a synthetic cyclic heptapeptide developed as an analogue of alpha-melanocyte-stimulating hormone, a naturally occurring peptide involved in pigmentation and appetite signalling. Its structure contains seven amino acid residues joined by a lactam bridge that closes the ring between two side chains. The molecular formula is C50H68N14O10 and the nominal molecular mass is near 1025 daltons. Much of the early laboratory literature refers to the same molecule by the development code PT-141.
| Property | Value | Notes |
|---|---|---|
| Primary receptor family | Melanocortin (MC1 to MC5) | Agonist activity reported at several subtypes |
| Signalling pathway | Gs, adenylyl cyclase, cyclic AMP | Canonical melanocortin signalling route |
| Backbone length | Seven amino acids | Classified as a cyclic heptapeptide |
| Ring closure | Lactam bridge | Constrains conformation and resists peptidases |
| Terminal modifications | Acetylated N-terminus, amidated C-terminus | Reduces breakdown by exopeptidases |
Certificate of analysis documents usually report purity percentage, molecular weight, and appearance. Researchers verify identity by comparing observed and theoretical mass values. Chain-of-custody records and batch numbers help trace material from source to experiment. Independent verification of supplier claims is considered good practice when material identity is critical to a study. Records should include the storage history of each aliquot, and unexpected deviations in appearance or solubility warrant re-testing before use.
Lyophilized peptide material is generally stored at -20 °C or below to limit degradation, while reconstituted solutions are less stable and are typically kept refrigerated and protected from light. Repeated freeze-thaw cycles can accelerate aggregation and should be minimized. Stability for any specific lot depends on purity, moisture content, and packaging. Handling in a temperature-controlled environment reduces variability across replicates, and exposure to ambient humidity during weighing can introduce error. Aliquotting reduces the number of times a stock container is opened.
Reverse-phase high-performance liquid chromatography is the standard method for assessing purity. Mass spectrometry confirms molecular identity and detects sequence variants or truncation products. Ultraviolet absorbance at 214 or 280 nm is used for quantification, with the choice depending on the peptide sequence. Method validation typically addresses linearity, limit of detection, and precision across a defined concentration range. Impurity profiling may also employ ion-exchange or size-exclusion chromatography, and these techniques complement one another.
Reported pharmacodynamic effects include transient rises in blood pressure and heart rate, flushing, nausea and headache, appearing soon after dosing and resolving within hours. These responses were dose-related in early studies and shaped the label's cardiovascular cautions and blood pressure monitoring advice. Gastrointestinal upset is the most frequent reason cited for discontinuation in trials. Whether the vascular signal attenuates with repeated use is not settled. Central effects on desire are described as emerging over weeks rather than immediately, which points to a cumulative rather than acute process.
The compound binds several melanocortin receptor subtypes rather than a single target, with the strongest functional activity reported at MC4R and measurable activity at MC1R, MC3R and MC5R. MC4R populations are dense in hypothalamic nuclei that integrate energy balance, autonomic tone and reproductive behaviour, which is the anatomical basis for the proposed pro-desire effect. Because binding is not subtype-selective, pigmentary and vascular effects accompany central activity. Improving subtype selectivity is an active area of analogue design. Direct causal mapping from receptor occupancy to reported desire change in humans is not fully established.
=== Jcom radio libel case === In November 2007, Jewish radio station Jcom aired a satirical segment in which a character named 'Georgie Galloway' used the anti-Semitic catchphrase "kill the Jews, kill the Jews". Galloway sued the station for libel and won the case in the High Court. Galloway was awarded £15,000 in damages and around £5,000 in costs. The radio station closed after losing the case. Galloway said the judgment had "categorically crushed the slur of anti-Semitism" against him.
Additionally, the intent of the regulations is to create a system that "should be a unified, standardized, and orderly processing of waste oil collection and improvement of the transportation system". The second set of regulations by the city of Beijing, called the "Beijing Municipal Solid Waste Regulations", was passed in September 2011. The regulations specifically target the two sources of gutter oil: food waste and used oil. The central government intends for these two sets of regulations to serve as national examples, yet wants every municipality nationally to find their own solutions to the food waste and gutter oil problem. A nationwide campaign was set in motion in August 2011 to crack down on the widespread production and selling of gutter oil. The law enforcement campaign uncovered 100 gutter oil manufacturers and arrested more than 800 people allegedly involved in the production and sale of gutter oil. In April 2012, another crackdown occurred with an additional 100 arrests made and 13 illegal workshops closed down across four provinces. According to a notice released jointly by the Supreme People's Court, the Supreme People's Procuratorate and the Ministry of Public Security, the death penalty will now be an option when prosecuting more serious cases of gutter oil manufacturing in the country. More severe punishments will also be given out to government and public officials who fail to properly address matters related to gutter oil.
adenosine monophosphate (AMP) A nucleoside consisting of adenosine attached to a single phosphate group via a high-energy ester bond. Additional phosphate groups can be added to AMP to produce ADP and ATP; the cyclic ester of AMP serves as a second messenger in some signaling pathways.
=== Extracellular signalling and neurotransmission === Cells secrete ATP to communicate with other cells in a process called purinergic signalling. ATP serves as a neurotransmitter in many parts of the nervous system, modulates ciliary beating, affects vascular oxygen supply etc. ATP is either secreted directly across the cell membrane through channel proteins or is pumped into vesicles which then fuse with the membrane. Cells detect ATP using the purinergic receptor proteins P2X and P2Y. ATP has been shown to be a critically important signalling molecule for microglia - neuron interactions in the adult brain, as well as during brain development. Furthermore, tissue-injury induced ATP-signalling is a major factor in rapid microglial phenotype changes.
Sources: en.wikipedia.org
=== Ethanol precipitation === Ethanol precipitation is a widely used method for purifying and concentrating nucleic acids, including plasmid DNA. The basic principle of this method is that nucleic acids are insoluble in ethanol or isopropanol but soluble in water. Therefore, it works by using ethanol as an antisolvent of DNA, causing it to precipitate out of solution and then it can be collected by centrifugation. The soluble fraction is discarded to remove other biomolecules.
==== Tzield ==== In the 1980s, Breakthrough T1D began funding basic research into disease-modifying therapies which can slow, halt, or reverse the progression of a disease. Breakthrough T1D continued research and strategic investments of this kind for decades. In 2019, Breakthrough T1D, in partnership with the NIH, funded a clinical trial that led to the 2022 FDA approval of teplizumab (Tzield), the first disease-modifying therapy for T1D.
On 1 May 1999 Pudzianowski entered his first Strongman competition, held in Płock, Poland. He achieved his first major success at the international level at the 2000 World's Strongest Man contest where he finished fourth in his first WSM competition. Due to his prison sentence, he did not return for the 2001 competition. Pudzianowski returned at the 2002 World's Strongest Man and won his first title. He retained his title at the 2003 World's Strongest Man with an event to spare, winning by the largest margin ever achieved in the competition; across the seven disciplines in the final, he scored a remarkable four first place finishes, two second place finishes and one third place finish, resulting in the points margin between first and second (20) being greater than the margin between second and ninth (18). British strongman Laurence Shahlaei has since called this performance the most dominant victory ever seen at a World's Strongest Man event. In March 2004, he also became the Strongman Super Series World Champion. He initially finished third in the 2004 World's Strongest Man but was later disqualified for breaching the governing body's Strongman Health Policy. He was forced to return his prize money, stripped of the International Federation of Strength Athletes points from the event, and received a one-year ban from competition. Pudzianowski did not dispute his banned substance violation and waived his right to have his stool sample verified. In 2005, he made his return to World's Strongest Man event.
Perineural cysts were first described by Dr. Isadore Tarlov in 1938. While conducting anatomical dissections of 30 human cadavers to study the filum terminale and lower spinal nerve roots, Tarlov identified cystic lesions on the S2 to S5 sacral nerve roots in five specimens, ranging in size from a pinhead to approximately 2 cm. He also reported degenerative changes in the nerve fibers, ganglion cells, and disintegration of myelin sheaths. These observations were published in a paper titled "Perineurial Cysts of the Spinal Nerve Roots (1938)", in which he suggested the possible clinical relevance of the cysts, stating: "One wonders whether they may not be responsible for the discomfort in certain cases of sciatica or nerve root pains, in which any other pathologic basis has been excluded. This awaits further studies with clinical and pathologic correlations." In 1948, Tarlov reported the first clinical case linking sacral perineural cysts to sciatic pain, establishing their potential as a treatable cause of radiculopathy. He described a 42-year-old woman who developed persistent right-sided sciatica following a fall. Although a herniated intervertebral disc was initially diagnosed, surgical exploration revealed a perineural cyst arising from the right S2 sacral nerve root, located under the posterior arch of the sacrum. The lesion was excised along with part of the dorsal root and ganglion. Postoperatively, the patient experienced significant improvement in motor function, pain, and sensation, without complications.
==== Combination drugs ==== Butalbital/acetaminophen (Butapap) – combination of butalbital (GABAA receptor positive allosteric modulator and barbiturate) and acetaminophen (analgesic) Ergotamine/caffeine (Cafergot) – combination of ergotamine (non-selective monoamine receptor modulator and ergoline) and caffeine (adenosine receptor antagonist) Ergotamine/chlorcyclizine/caffeine (Anervan) – combination of ergotamine (non-selective monoamine receptor modulator and ergoline), chlorcyclizine (antihistamine and other actions), and caffeine (adenosine receptor antagonist) Meloxicam/rizatriptan (AXS-07; Symbravo) – combination of meloxicam (COX inhibitor/NSAID) and rizatriptan (triptan) [139] Naproxen sodium/sumatriptan (MT-400; SumaRT/Nap; Suvexx; Trexima; Treximet) – combination of naproxen (COX inhibitor/NSAID) and sumatriptan (triptan) – migraine [140] Paracetamol/codeine/buclizine (Migraleve Yellow) – combination of paracetamol (analgesic) and codeine (opioid) Paracetamol/codeine/buclizine (Migraleve Pink) – combination of paracetamol (analgesic), codeine (opioid), and buclizine (antihistamine and other actions) Paracetamol/dichloralphenazone/isometheptene (Amidrine) – combination of paracetamol (analgesic), dichloralphenazone (phenazone (COX inhibitor/NSAID) and chloral hydrate (GABAA receptor positive allosteric modulator)), and isometheptene (adrenergic receptor agonist) Paracetamol/metoclopramide (Paramax) – combination of paracetamol (analgesic) and metoclopramide (various actions) Sumatriptan/naproxen (Treximet) – combination of sumatriptan (triptan) and naproxen (COX inhibitor/NSAID)
Sources: en.wikipedia.org
It is frequently described as an MC4 receptor agonist, but binding assays show activity at more than one melanocortin subtype. Selectivity is therefore relative rather than absolute. This matters when interpreting side effects tied to other receptor subtypes.
The lactam bridge locks the peptide into a defined shape and makes it harder for peptidases to cut the backbone. Terminal blocking groups add further protection at both ends. Together these features extend the molecule's persistence in circulation compared with linear peptides.
Evidence from animals favors hypothalamic melanocortin circuits, yet direct confirmation in humans is lacking. A peripheral vascular contribution has also been proposed. How receptor binding translates into a reported behavioral effect is still not mapped.
It is a synthetic cyclic peptide that acts as an agonist at melanocortin receptors. It is not a hormone replacement therapy and not a vasodilator in the usual clinical sense, although it does affect vascular tone. Chemically it belongs to the melanocortin analogue family.